What's in Amgen's Q4 Earnings prescription?
JHVEPhoto/iStock Editorial via Getty Images


Amgen (NASDAQ:AMGN) is scheduled to announce Q4 earnings results on Monday, February 7th, after market close.
The consensus EPS Estimate is $4.05 (+6.3% Y/Y) and the consensus Revenue Estimate is $6.88B (+3.8% Y/Y).
Over the last 2 years, AMGN has beaten EPS estimates 88% of the time and has beaten revenue estimates 88% of the time.

Over the last 3 months, EPS estimates have seen 11 upward revisions and 5 downward. Revenue estimates have seen 5 upward revisions and 11 downward.
The company in its Q3 earnings provided 2021 guidance:



In Q4, though the company is likely to have seen a continued recovery in patient visits and diagnoses rates, new patient starts may have remained suppressed due to a gap in doctor office visits amid rising infection rates due to the Omicron variant.
Amgen along with Generate Biomedicines in early January announced a research collaboration agreement to discover and create protein therapeutics for five clinical targets across several therapeutic areas and multiple modalities.
In early January, Amgen was downgraded to Neutral at BofA as, "growth skepticism" is likely to persist until the company demonstrates a clear return to "strong, volume-driven revenue upside" for several of its key franchises.
SA Contributor Daniel SchÃ¶nberger believes that Amgen is still a good pick for bargain hunters while SA Contributor Khen Elazar believes that the stock is still a fit for your dividend growth portfolio.


Wall Street Analysts average rating stands at Hold while SA Author rating is at Buy.

Quant rating is as below: